Current Trends and Challenges in India’s Pharmaceutical Sector

Abstract

The Indian pharmaceutical industry is one of the largest and fastest growing sectors globally, playing a crucial role in healthcare innovation, affordability and accessibility. With a strong foundation in generic drug manufacturing, India supplies over 20% of the global demand for generic medicines. The sector has witnessed significant advancements driven by govemment initiatives increase foreign investment and technology innovation, including artificial intelligence and precision medicine. The review highlights the current trends, opportunity and challenges shaping the Indian pharmaceutical industry emphasizing the need for sustainable growth through policy reforms, innovation and self-reliance in ATP production,

Keywords

Indian pharmaceutical industry, Healthcare innovation, Artificial intelligence, Generic Drugs, Biopharmaceuticals, Biosimilars, E-pharmacies, Digital Health, Research and Development, Price Controls, etc

Introduction

India's pharmaceutical sector is a global powerhouse, recognized for its substantial contribution to the supply of affordable generic drugs, vaccines, and active pharmaceutical ingredients (APIs). As the world's largest supplier of generic medicines, India plays a pivotal role in addressing the growing global demand for cost-effective healthcare solutions. The industry is poised for continued growth, driven by advancements in biopharmaceuticals, digital health technologies, and a robust research and development (R&D) ecosystem. However, despite these opportunities, the sector faces several challenges, including regulatory complexities, price control policies, counterfeit drugs, and dependence on raw material imports. Additionally, the industry must tackle skill gaps and improve drug quality control to maintain its competitiveness in the global market. This dynamic landscape presents both tremendous potential and significant hurdles, shaping the future of India's pharmaceutical industry. India's pharmaceutical sector is a key player in the global healthcare market, known for its leadership in the production of generic drugs, vaccines, and active pharmaceutical ingredients (APIs).[12] With a growing focus on biopharmaceuticals, digital health, and research & development, the industry is expanding rapidly. However, challenges such as regulatory hurdles, price controls, counterfeit drugs, and dependency on raw material imports remain significant. Despite these obstacles, India’s pharmaceutical industry continues to thrive, contributing substantially to global healthcare and poised for future growth. India's pharmaceutical industry is one of the largest and most dynamic in the world, playing a crucial role in meeting the global demand for affordable medicines. It is a major exporter of generic drugs, contributing significantly to global healthcare by supplying over 50% of the world’s vaccines and around 40% of U.S. generic drug consumption. The sector has experienced remarkable growth, fueled by advancements in biopharmaceuticals, an increasing shift toward personalized medicine, and the adoption of digital health technologies like e-pharmacies and telemedicine.[14]

Despite its success, the Indian pharmaceutical industry faces several challenges that could hinder its growth. Regulatory complexities, intellectual property issues, price controls on essential medicines, and the prevalence of counterfeit drugs continue to pose significant barriers. Additionally, the industry's reliance on raw material imports, particularly from China, exposes it to potential supply chain disruptions. The sector also faces a skill gap in specialized areas such as research and development, regulatory compliance, and advanced manufacturing.[11] In light of these challenges, India’s pharmaceutical sector must innovate, address regulatory and quality control issues, and invest in infrastructure and talent development to sustain its leadership in the global market. With continued focus on research, development, and digital transformation, the Indian pharmaceutical industry is well-positioned to meet the evolving healthcare needs of the world.

History of India’s pharmaceutical sector

The history of India's pharmaceutical sector is a story of rapid growth, innovation, and global influence. Here’s a brief overview of its evolution:

Early Beginnings (Pre-Independence Era)

• Traditional Medicine: Before the advent of modern pharmaceuticals, India had a rich tradition of herbal and Ayurvedic medicine. Many plants and herbs were used for healing, and this knowledge was passed down through generations.[21]
• Colonial Influence: During British colonial rule (1858-1947), India’s pharmaceutical industry remained largely underdeveloped, with most medicines being imported from Western countries. Few indigenous pharmaceutical companies existed, and the industry relied heavily on foreign pharmaceutical products.

Post-Independence Growth (1947-1970s)[20]

• Independence and Nationalization: After gaining independence in 1947, India aimed to reduce its reliance on foreign medicines. The government sought to develop a self-sufficient pharmaceutical industry, which would cater to the growing demand for medicines across the country.
• Public Sector Initiatives: In the 1950s and 1960s, the government began establishing public sector pharmaceutical companies, such as Indian Drugs and Pharmaceuticals Limited (IDPL) and Hindustan Antibiotics Ltd. (HAL), to promote domestic production. These initiatives aimed to improve drug accessibility and affordability.
• The 1970 Patent Act: A landmark moment in the development of India’s pharmaceutical industry occurred in 1970 with the enactment of the Patents Act. The Act allowed the production of generic versions of patented drugs, enabling Indian companies to manufacture low-cost alternatives to patented drugs. This led to the rise of India’s generic drug market, making medicines more affordable and accessible.

Rise of the Generic Industry (1980s-1990s)

• Expansion of Domestic Pharma Companies: In the 1980s and 1990s, several Indian pharmaceutical companies, such as Dr. Reddy’s Laboratories, Cipla, Ranbaxy, and Lupin, grew significantly by producing affordable generic drugs. They began to challenge multinational pharmaceutical companies by offering high-quality, low-cost alternatives.[7]
• Export Growth: During this period, India began expanding its pharmaceutical exports, particularly to developing countries in Africa and Asia. By the early 1990s, India had established itself as a major supplier of generics worldwide.
• Economic Liberalization: The liberalization of the Indian economy in the early 1990s helped the pharmaceutical industry grow by opening up new markets and encouraging foreign direct investment (FDI). The industry became more globalized and integrated into international markets.[9]

Globalization and Innovation (2000s-Present)

• WTO and TRIPS Agreement: India’s pharmaceutical industry faced new challenges in the 2000s with the implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) under the World Trade Organization (WTO) agreement. Under TRIPS, India was required to grant product patents for pharmaceuticals, which limited the production of generics for patented drugs. However, India’s Patents Act of 1970 was modified to balance patent protection with the ability to produce generics, most notably through the Novartis vs. Union of India case in 2007, where the Supreme Court ruled that the patent for the cancer drug Glivec was not granted in India due to lack of innovation.
• Innovation and R&D Growth: In the 2000s, Indian pharmaceutical companies started focusing more on research and development (R&D) and innovation. Companies like Dr. Reddy’s Laboratories and Biocon invested in developing new chemical entities (NCEs), biosimilars, and biologics. India became a hub for clinical trials and contract research and manufacturing services (CRAMS).[17]
• Global Market Leadership: India’s pharmaceutical sector became the world’s largest supplier of generic medicines, including over 50% of global vaccine demand. The country’s pharmaceutical exports to the U.S., Europe, and other global markets grew exponentially.

Recent Developments (2010s-2020s)

• Biosimilars and Biopharmaceuticals: The rise of biopharmaceuticals and biosimilars has positioned India as a leader in the global biosimilars market. Companies like Biocon and Cipla have gained recognition for their development of affordable biosimilars.[21]
• COVID-19 and Vaccine Production: India’s pharmaceutical industry played a pivotal role in responding to the COVID-19 pandemic, with companies like Serum Institute of India and Bharat Biotech developing and producing vaccines. India also became a key supplier of vaccines globally through the COVAX initiative.
• Digital Transformation: The sector is undergoing a digital revolution, with the rise of e-pharmacies, telemedicine, and digital health solutions. The government is also promoting initiatives such as Ayushman Bharat to enhance access to affordable healthcare.[27]

Future Outlook

The future of India’s pharmaceutical sector looks promising, driven by continued innovation, advancements in biotechnology, and a growing focus on personalized medicine. However, challenges such as regulatory complexities, intellectual property concerns, and global competition must be addressed for the sector to maintain its global leadership. In conclusion, India’s pharmaceutical sector has come a long way from its early dependence on foreign medicines to becoming a global leader in generic drug production, innovation, and pharmaceutical exports. The sector continues to evolve with new trends, technologies, and opportunities, positioning India as a key player in the global healthcare industry.[19]

Recent Developments

Recent developments in India’s pharmaceutical sector reflect a combination of innovation, strategic expansion, and adaptations to global challenges. Some of the key trends and advancements in recent years include:

1. Growth of Biosimilars and Biopharmaceuticals:

• India has emerged as a global leader in the biosimilars market, with companies like Biocon, Cipla, and Dr. Reddy's Laboratories making significant strides in the development and commercialization of biosimilar drugs. Biosimilars are affordable alternatives to expensive biologic drugs, and India is positioning itself as a manufacturing hub for these complex therapies.
• Indian pharmaceutical companies are also increasingly investing in biopharmaceuticals, expanding their portfolios to include advanced therapies for cancer, autoimmune diseases, and other chronic conditions.[24]

2. COVID-19 Response and Vaccine Production:

• India played a pivotal role in the global response to the COVID-19 pandemic. Serum Institute of India (SII), the world’s largest vaccine manufacturer, produced the Covishield vaccine in partnership with AstraZeneca. Bharat Biotech developed the Covaxin vaccine, contributing significantly to India’s vaccination efforts.
• The country has become a key supplier of vaccines to other nations, both through the COVAX initiative and direct bilateral agreements, reinforcing its reputation as a global leader in vaccine production.[22]

3. Digital Transformation and E-Pharmacies:

• The rise of e-pharmacies in India, accelerated by the pandemic, has reshaped the pharmaceutical retail landscape. Companies like 1mg, PharmEasy, and Netmeds have gained significant traction, offering home delivery of medicines, diagnostic services, and consultations.
• Telemedicine and digital health platforms have also seen rapid adoption, contributing to enhanced healthcare access, especially in rural areas. Government initiatives like Ayushman Bharat Digital Mission aim to integrate technology into healthcare delivery across India.

4. Investment in Research and Development (R&D):

• There has been a continued focus on strengthening R&D capabilities in India’s pharmaceutical sector. Companies like Dr. Reddy’s Laboratories, Lupin, and Cadila Healthcare are increasingly investing in the development of new chemical entities (NCEs), generic formulations, and biologics.
• India’s pharmaceutical companies are expanding their research in precision medicine, leveraging genomics and biotechnology to create tailored treatments for patients based on their genetic makeup.[18]

5. Expansion of Pharmaceutical Exports:

• India has strengthened its position as the world's largest supplier of generics. Pharmaceutical exports from India have increased, with major markets including the United States, Europe, and Africa. The country also remains the largest exporter of vaccines globally, ensuring access to affordable healthcare in developing regions.
• India’s pharmaceutical sector is increasingly tapping into emerging markets in Africa, Latin America, and Southeast Asia, driven by the rising demand for affordable medicines.[21]

6. Regulatory Reforms and Strengthened Compliance:

• India has been taking steps to improve regulatory frameworks and ensure higher standards in drug quality. The Central Drugs Standard Control Organization (CDSCO) has been working on enhancing compliance with international standards, especially in areas like Good Manufacturing Practices (GMP).
• The National Biotechnology Development Strategy and initiatives like Pharma Vision 2020 aim to strengthen India’s regulatory and quality control mechanisms to align with global pharmaceutical standards.[13]

7. Collaboration with Global Pharma Giants:

• Indian pharmaceutical companies have increasingly entered into strategic partnerships and collaborations with global pharmaceutical giants. These collaborations focus on co-development of new drugs, biosimilars, and vaccines, boosting India’s position as a global player in drug manufacturing.
• For example, Dr. Reddy’s Laboratories has partnered with Eli Lilly for the development and commercialization of new treatments, while Cipla has collaborated with Boehringer Ingelheim to co-develop biologic therapies.

8. Focus on Sustainability and Green Chemistry:

• Indian pharmaceutical companies are also focusing on sustainable manufacturing practices. Companies are adopting green chemistry practices, reducing environmental impact through energy-efficient technologies, waste management solutions, and eco-friendly packaging.
• The Indian pharmaceutical sector is increasingly exploring alternative and sustainable sources for key raw materials and APIs, in response to global supply chain disruptions.

9. Expansion of Contract Research and Manufacturing Services (CRAMS):

• India has continued to solidify its position as a hub for contract research and manufacturing services (CRAMS), offering cost-effective and high-quality services to global pharmaceutical companies.
• Indian firms like Syngene International and Sudarshan Pharma have expanded their CRAMS operations, providing services such as drug discovery, clinical trials, and contract manufacturing to international clients.[29]

10. Government Initiatives and Support:

• The Indian government has introduced various initiatives to support the pharmaceutical sector, including the Production Linked Incentive (PLI) scheme, aimed at boosting domestic manufacturing of critical pharmaceutical ingredients and medical devices.
• Initiatives like Pharma Vision 2020 and Atmanirbhar Bharat (Self-Reliant India) focus on reducing dependency on foreign imports, promoting indigenous drug production, and strengthening the sector's global competitiveness.

Current Trends

The Indian pharmaceutical sector is undergoing significant transformation, driven by several key trends that are shaping its future. Here are some of the most notable current trends:

1. Growth in Biopharmaceuticals and Biosimilars:

• India is becoming a hub for biopharmaceuticals and biosimilars, with companies like Biocon, Cipla, and Dr. Reddy’s Laboratories leading the charge. Biosimilars, which are affordable alternatives to biologic drugs, are gaining traction, especially in oncology, autoimmune diseases, and chronic conditions.
• With growing demand for biologics worldwide, India is positioning itself as a low-cost producer of biosimilars, benefiting from the expertise of its biopharmaceutical companies.[8]

2. Digital Transformation and E-Pharmacies:

• E-pharmacies and telemedicine are becoming increasingly popular in India. Companies like 1mg, PharmEasy, and Netmeds are gaining market share by offering online medicine deliveries, diagnostic services, and consultations.
• The digital health ecosystem is expanding, with telehealth and digital solutions enabling greater healthcare access, especially in rural areas. The government’s Ayushman Bharat Digital Mission aims to integrate digital platforms with healthcare services across the country.[10]

3. Expansion of Contract Research and Manufacturing Services (CRAMS):

• India is positioning itself as a leading hub for contract research and manufacturing services (CRAMS). Indian pharmaceutical companies are offering cost-effective, high-quality services for global pharmaceutical companies, ranging from drug discovery to clinical trials and manufacturing.
• Companies like Syngene International and Biocon are expanding their CRAMS services, capitalizing on the growing outsourcing trends in the global pharmaceutical industry.[20]

4. Focus on Sustainability and Green Chemistry:

• There is a growing emphasis on sustainable manufacturing practices and green chemistry within the pharmaceutical sector. Companies are adopting energy-efficient technologies, reducing carbon footprints, and working towards eco-friendly production methods.
• India’s pharmaceutical sector is exploring sustainable raw material sourcing and waste management techniques, in response to environmental concerns and global supply chain disruptions.

5. Regulatory Improvements and Quality Control:

• The Indian government, through regulatory bodies like the Central Drugs Standard Control Organization (CDSCO), is focusing on improving the quality control and regulatory compliance of pharmaceutical products. Efforts to align with international standards (such as GMP and FDA guidelines) are being strengthened to improve India’s global competitiveness.[21]
• There is an increasing push for stricter monitoring and quality assurance to combat counterfeit drugs, ensuring higher standards of safety for domestic and export markets.

6. Personalized and Precision Medicine:

• The rise of personalized medicine and precision therapeutics is a growing trend in India. Advances in genomics, biotechnology, and data analytics are enabling healthcare providers to offer treatments tailored to individual genetic profiles.
• Indian pharmaceutical companies are investing in research related to genomic sequencing and biomarker-based treatments, which are expected to drive growth in targeted therapies for diseases like cancer.[27]

7. Vaccine Development and Production Leadership:

• India continues to be a global leader in vaccine production. The Serum Institute of India (SII) and Bharat Biotech have played pivotal roles in the development and distribution of vaccines, including the COVAXIN and COVISHIELD vaccines for COVID-19.
• India remains a key supplier of vaccines to low and middle-income countries, significantly contributing to global immunization programs and playing an essential role in initiatives like COVAX.

8. Focus on Export Growth:

• The Indian pharmaceutical industry continues to see strong export growth. India remains the largest supplier of generic medicines to global markets, including the United States, Europe, and Africa.[25]
• India’s pharmaceutical exports are growing, particularly in emerging markets, and are supported by the government's Production Linked Incentive (PLI) scheme, which encourages domestic manufacturing of critical drugs and active pharmaceutical ingredients (APIs).

9. Mergers, Acquisitions, and Strategic Partnerships:

• The Indian pharmaceutical sector is experiencing a wave of mergers and acquisitions (M&As), as companies seek to expand their portfolios, enter new markets, or strengthen R&D capabilities. Notable partnerships between Indian pharmaceutical firms and global giants are becoming more common.
• Companies are also increasingly focusing on strategic collaborations to develop new drugs, biosimilars, and other therapies to meet growing global demand.

10. Increased Focus on Rare and Orphan Drugs:

• There is a rising interest in the development of rare diseases and orphan drugs within India’s pharmaceutical industry. As India’s healthcare system evolves, pharmaceutical companies are turning their attention to treating conditions that have smaller patient populations, thereby filling a gap in global healthcare markets.
• The government's focus on regulatory reforms and incentives for companies developing drugs for rare diseases is creating new opportunities in this specialized segment.[22]

Challenges

India’s pharmaceutical sector, despite its impressive growth and global prominence, faces several challenges that need to be addressed to maintain its leadership position. These challenges range from regulatory hurdles to global competition, and they can impact the industry’s efficiency, sustainability, and future growth. Below are some of the key challenges currently faced by India’s pharmaceutical sector:

1. Regulatory and Compliance Challenges:

• Stringent Global Regulations: As the sector expands its global footprint, Indian pharmaceutical companies must comply with diverse and often complex regulatory standards set by markets like the U.S. FDA and European Medicines Agency (EMA). This can be costly and time-consuming for companies, especially smaller ones.
• Slow Regulatory Approvals: Regulatory delays, both at the domestic and international levels, can slow down the approval process for new drugs, biosimilars, and generics, affecting timely market entry.
• Quality Control and Counterfeit Drugs: Ensuring consistent quality control is a persistent challenge, especially with the rise in the prevalence of counterfeit and substandard drugs. This undermines trust in India’s pharmaceutical exports and poses serious public health risks.[20]

2. Intellectual Property and Patent Issues:

• Patent Conflicts and Patent Evergreening: India’s 1970 Patents Act allows generic drug manufacturing by circumventing patents, which often leads to conflicts with multinational pharmaceutical companies over patent rights. While India supports affordable access to medicine, disputes regarding intellectual property (IP) can hinder innovation and market access.
• TRIPS Compliance: The global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement mandates India to grant product patents, affecting the generic drug business and challenging companies to balance innovation with cost-effective solutions.

3. Dependence on Raw Material Imports:

• API (Active Pharmaceutical Ingredients) Imports: India is highly dependent on imports for key raw materials, especially from China. This exposes the sector to supply chain disruptions, particularly in the event of geopolitical tensions or trade restrictions.
• Supply Chain Vulnerability: The reliance on imported APIs makes the industry vulnerable to global supply chain issues, as seen during the COVID-19 pandemic, which caused significant disruptions in the production of pharmaceutical products.[14]

4. Price Control Regulations:

• Government-Imposed Price Caps: The Indian government has implemented price controls on essential drugs through the National List of Essential Medicines (NLEM) and the Pharmaceuticals Price Control Order (PPCO). While these controls aim to ensure affordability, they can affect the profitability of pharmaceutical companies, especially those involved in the production of patented or specialized drugs.
• Limited Flexibility in Pricing: The pressure to keep prices low for domestic consumption can limit the ability of companies to reinvest in innovation or R&D, particularly in a highly competitive global market.[17]

5. Counterfeit and Substandard Drugs:

• Prevalence of Counterfeit Drugs: The market for counterfeit drugs in India is a significant issue, leading to health risks and a loss of consumer trust. This not only affects the domestic market but also India’s reputation as a reliable global supplier.
• Regulation and Enforcement: While the government has introduced initiatives to crack down on counterfeit drugs, enforcement remains a challenge. Increased vigilance and robust tracking systems are needed to curb this growing problem.

6. Skilled Workforce Shortage:

• Talent Gap: There is a growing shortage of skilled professionals in areas such as research and development (R&D), regulatory affairs, and advanced manufacturing. The industry needs a highly skilled workforce to stay competitive in fields like biologics, biosimilars, and personalized medicine.
• Lack of Specialized Training: Although India has a large pool of engineering and science graduates, there is often a lack of specialized training in pharmaceutical sciences, which could hinder innovation and quality control efforts.[24]

7. Rising Competition from Global Pharmaceutical Markets:

• Global Competitors: India faces increasing competition from other emerging markets like China, South Korea, and Brazil, which are investing heavily in their pharmaceutical industries. These countries are developing their own capabilities in generics, vaccines, and biologics, making the global market more competitive.
• Price Wars and Generic Drug Competition: While India is a leader in generics, other countries are becoming more aggressive in producing low-cost generic alternatives, leading to price wars that can impact profit margins for Indian pharmaceutical firms.

8. Environmental and Sustainability Concerns:

• Environmental Impact of Manufacturing: The environmental footprint of pharmaceutical manufacturing, including waste disposal, emissions, and water usage, is a growing concern. The industry must adopt more sustainable practices, but this often involves additional investment and regulatory scrutiny.
• Pressure for Green Chemistry: There is an increasing push from governments and consumers to adopt green chemistry and more eco-friendly manufacturing processes. However, transitioning to these practices can be expensive and logistically challenging for many pharmaceutical companies.

9. Innovation and R&D Challenges:

• Funding for Innovation: While large companies like Dr. Reddy’s Laboratories and Biocon invest heavily in R&D, smaller firms often struggle with limited access to funding for new drug development, particularly in niche areas such as rare diseases, biologics, and personalized medicine.
• High R&D Costs: The high costs associated with drug discovery, clinical trials, and regulatory approval can limit innovation, especially for companies focused on low-cost generics.[23]

10. Infrastructure and Logistics Issues:

• Inadequate Infrastructure: Despite progress, India’s pharmaceutical industry still faces challenges related to inadequate infrastructure in certain regions, especially in terms of storage, distribution, and transportation of sensitive medicines that require specific temperature controls.
• Logistical Barriers: The country’s complex logistics network can lead to delays in the distribution of drugs both domestically and internationally, affecting timely market access and supply chain efficiency.[26]

CONCLUSION:

India’s pharmaceutical sector has firmly established itself as a global leader in the production of generics, biosimilars, vaccines, and active pharmaceutical ingredients (APIs). With a strong emphasis on cost-effective manufacturing and innovation, the industry has made significant contributions to global healthcare, providing affordable medicines to millions. However, the sector faces a range of challenges that must be addressed to ensure sustainable growth and maintain its competitive edge. Regulatory complexities, dependence on imported raw materials, and rising competition from other emerging markets are key hurdles that require attention. Additionally, concerns over counterfeit drugs, price control measures, and the need for a highly skilled workforce add to the complexity of the landscape. The industry must also prioritize sustainability and environmental responsibility while fostering continued innovation in research and development (R&D). Despite these challenges, the Indian pharmaceutical industry is well-positioned to leverage its strengths in generics and biopharmaceuticals, driven by advancements in digital transformation, contract research and manufacturing, and global collaborations.

REFERENCES

1. Indian Pharmaceutical Industry: An Overview Gulshan Akhtar, IOSR Journal Of Humanities And Social Science (IOSR-JHSS), Volume 13, Issue 3 (Jul. - Aug. 2013), PP 51-66
2. M. Mazumdar, Performance of Pharmaceutical Companies in India, Contributions to Economics, DOI 10.1007/978-3-7908-2876-4_2, Springer- Verlag Berlin Heidelberg, 2013
3. Reji K Joseph,The R&D Scenario in Indian Pharmaceutical Industry, Research and Information System for Developing Countries, RIS-Discussion Paper # 176, December 2011.pp.8
4. “5” challenges faced by the pharma industry – IIPTA, APRIL 3, 2015,
5. Indian pharma market isn?t going to be that rosy - The Hindu, September 29, 2013, Interview with Glenn Saldanha, Chairman & Managing Director Glenmark Pharmaceuticals,
6. M Janodia, S Pandey, J Venkara Rao, D Sreedhar, V Ligade, N Udupa. Patents Regime in India: Issues, challenges and opportunities in Pharmaceutical Sector. The Internet Journal of Third World Medicine. 2007 Volume 7 Number 1.
7. Industry Report, Healthcare: India, The Economist Intelligence Unit, July 2014
8. Driving towards marketing excellence, McKinsey & Company.2008
9. PwC Report India Pharma Inc.:Changing landscape of Indian pharma industry, 2013
10. Organization of Pharmaceutical Producer in India Report. Indian Pharmaceutical Industry Challenges, July 2014,
11. INDIA-OPPORTUNITIES, A guide to do business in India. available at http://www.indiaopportunities.es/pharmaceuticalindustry.php?lang=ing website maintained Commercial Wing Embassy of India Madrid
12. Indian Brand Equity Foundation Report on Pharmaceutical Industry, January 2016
13. Annual Report, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, 2014-15
14. Global Use of Medicines in 2020.Out look and Implication, November 2015. Report by the IMS Institute for Healthcare Informatics.
15. www.pwc.com/india
16. www.imshealth.com
17. www.makeinindia.com/sector/pharmaceuticals '
18. www.bifr.org